Imaging with gadolinium does not put patients at risk for adverse neurologic outcomes later in life.
Gadolinium (Gd) exposure is not associated with adverse neurologic outcomes, according to a new study presented today at RSNA.
Researchers from the United States sought to study the effects of Gd exposure on neurologic and neurocognitive function. "It's estimated that approximately 400 million doses of gadolinium have been administered since 1988," said lead author, Robert J. McDonald, MD, PhD, a neuroradiologist at the Mayo Clinic in Rochester, MN. "Gadolinium contrast material is used in 40 to 50 percent of MRI scans performed today."
The researchers used data obtained from the Mayo Clinic Study of Aging (MCSA). They compared neurologic and neurocognitive scores using standard multivariate methods between MCSA patients with no history of prior Gd exposure and those who underwent prior Gd-enhanced MR imaging. Progression from normal cognitive status to mild-cognitive impairment and dementia was assessed using multistate Markov model analysis.
There were 4,261 cognitively normal study participants, aged 50-90 (mean age 71.9). Of these, 1,092 (25.6%) received one or more GBCA doses (median: 2 doses, range: 1 to 28 doses) unrelated to their participation in the MCSA. Median time since first Gd exposure was 5.6 years. After adjusting for age, sex, education level, baseline neurocognitive performance, Charlson comorbidity index, and ApoE4 status, GBCA exposure was not a significant predictor of cognitive decline with changes in clinical dementia rating, Blessed dementia scale, or mental status exam score. Nor was there diminished neuropsychological performance or diminished motor performance. No dose-related effects were observed among these metrics.
"Right now there is concern over the safety of gadolinium-based contrast agents, particularly relating to gadolinium retention in the brain and other tissues," McDonald said in the release. "This study provides useful data that at the reasonable doses 95 percent of the population is likely to receive in their lifetime, there is no evidence at this point that gadolinium retention in the brain is associated with adverse clinical outcomes."[[{"type":"media","view_mode":"media_crop","fid":"64661","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_9710982958645","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"8277","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 424px; width: 500px; float: right;","title":" MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red). ©RSNA 2017","typeof":"foaf:Image"}}]]
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.